Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
FDA approves Rozlytrek for cancers with certain gene mutations
Biomarker was not linked to response rates in two studies of Keytruda for lung cancer.
Selpercatinib shrank tumors in 68% of patients previously treated with chemotherapy.
A related study finds patient and provider perceptions about barriers to trial participation are not in sync.
Half of study participants treated with AMG 510 saw their tumors shrink, and only one experienced disease progression.
New site-agnostic therapy shrank tumors in people with a variety of cancers with NTRK gene fusions as well as ROS1-positive lung cancer.
People with HIV had low rates of complications similar to those of HIV-negative patients.
The results from an innovative, “virtual” clinical trial were presented at the 2019 ASCO Annual Meeting.
RET inhibitor shrank tumors in more than half of people with non-small-cell lung cancer and aggressive thyroid cancer.
The immunotherapy drug shows the most benefit for newly treated people with tumors that test positive for the PD-L1 biomarker.
ASCO and Friends of Cancer Research proposed new eligibility guidelines in 2017.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.